論文 - 詳細
| RRC ID | 1923 |
|---|---|
| 著者 | Kanno S, Tomizawa A, Hiura T, Osanai Y, Shouji A, Ujibe M, Ohtake T, Kimura K, Ishikawa M. |
| タイトル | Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. |
| ジャーナル | Biol Pharm Bull |
| Abstract |
We have investigated the effect of naringenin (NGEN) on tumor growth in various human cancer cell lines and sarcoma S-180-implanted mice. NGEN showed cytotoxicity in cell lines derived from cancer of the breast (MCF-7, MDA-MB-231), stomach (KATOIII, MKN-7), liver (HepG2, Hep3B, Huh7), cervix (Hela, Hela-TG), pancreas (PK-1), and colon (Caco-2) as well as leukemia (HL-60, NALM-6, Jurkat, U937). NGEN-induced cytotoxicity was low in Caco-2 and high in leukemia cells compared to other cell lines. NGEN dose-dependently induced apoptosis, with hypodiploid cells detected in both Caco-2 and HL-60 by flow cytometric analysis. In vivo, NGEN inhibited tumor growth in sarcoma S-180-implanted mice, following intraperitoneal or peroral injection once a day for 5 d. Naringin (NG) also inhibited tumor growth by peroral injection but not intraperitoneal injection. NGEN, one of the most abundant flavonoids in citrus fruits, may have a potentially useful inhibitory effect on tumor growth. |
| 巻・号 | 28(3) |
| ページ | 527-30 |
| 公開日 | 2005-3-1 |
| DOI | 10.1248/bpb.28.527 |
| PII | JST.JSTAGE/bpb/28.527 |
| PMID | 15744083 |
| MeSH | Animals Antineoplastic Agents / pharmacology* Cell Line, Tumor Dose-Response Relationship, Drug Drug Screening Assays, Antitumor / methods Flavanones / therapeutic use* Growth Inhibitors / pharmacology* Humans Male Mice Sarcoma 180 / drug therapy* Sarcoma 180 / pathology |
| IF | 1.863 |
| 引用数 | 144 |
| WOS 分野 | PHARMACOLOGY & PHARMACY |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 4 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | CACO-2(RCB0988) |